4-丁氧基哌啶 | 88536-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-丁氧基哌啶
• 英文名称: 4-(Butyloxy)piperidine
• 英文别名: 4-Butoxypiperidine
• CAS: 88536-10-1
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: XGPJZKQGJWZWIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-丁氧基哌啶 、 2-氯-6-三氟甲基烟腈 在 哌啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 4-butoxy-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile
  参考文献：
  名称：

  2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as Potent Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists: Structure–Activity Relationships of 2-Amino Derivatives in the N-(6-Trifluoromethylpyridin-3-ylmethyl) C-Region

  摘要：

  A series of N-(2-amino-6-trifluoromethylpyridin-3-ylmethyl)-2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides were designed combining previously identified pharmacophoric elements and evaluated as hTRPV1 antagonists. The SAR analysis indicated that specific hydrophobic interactions of the 2-amino substituents in the C-region of the ligand were critical for high hTRPV1 binding potency. In particular, compound 49S was an excellent TRPV1 antagonist (K-i(CAP) = 0.2 nM; IC50(pH) = 6.3 nM) and was thus approximately 100- and 20-fold more potent, respectively, than the parent compounds 2 and 3 for capsaicin antagonism. Furthermore, it demonstrated strong analgesic activity in the rat neuropathic model superior to 2 with almost no side effects. Compound 49S antagonized capsaicin induced hypothermia in mice but showed TRPV1-related hyperthermia. The basis for the high potency of 49S compared to 2 is suggested by docking analysis with our hTRPV1 homology model in which the 4-methylpiperidinyl group in the C-region of 49S made additional hydrophobic interactions with the hydrophobic region.

  DOI：

  10.1021/jm300780p
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 、 、 diisobutylaluminum hydride 、 、 Sodium potassium tartrate tetrahydrate 在 乙酸乙酯 、 Brine 、 magnesium sulfate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.33h， 生成 4-丁氧基哌啶
  参考文献：
  名称：

  4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity

  摘要：

  本发明涉及公式I的吡咯烷化合物：1（其中R1、R2、R3、R4c、R4d和R4f的定义见下文），它们可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。

  公开号：

  US20020013348A1

文献信息

• [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009125870A1

  公开（公告）日：2009-10-15

  A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.

  化合物的结构式（A）；其中环A是芳香环或杂芳环；R1独立地是卤素、氰基等；X1、X2和X3中的每一个是CR2或氮，R2独立地是氢等；n为0、1、2、3或4；-D-Y是-O-CH2COOH等；G是取代氨基、取代杂环基等，或其药用可接受盐，具有开放BK通道的活性。
• N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20100197703A1

  公开（公告）日：2010-08-05

  This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

  该发明提供了噻唑基哌嗪衍生物，以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物，以及其药学上可接受的盐，这些是用于治疗α-突触核蛋白病的有效活性成分，如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法，以及包括这些衍生物和药学上可接受的辅料的药物组合物。
• [EN] AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR<br/>[FR] INHIBITEUR DE METALLOPROTEASE A BASE D'ACIDE HYDROXAMIQUE AROMATIQUE SULFONÉ
  申请人：SEARLE & CO

  公开号：WO2000050396A1

  公开（公告）日：2000-08-31

  A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

  本发明公开了一种治疗过程，包括向患有与病理性基质金属蛋白酶活性相关的疾病的宿主施用一种具有出色抑制活性的芳香基磺酮羟肟酸的有效量，例如MMP-2、MMP-9和MMP-13，同时对至少MMP-1的抑制作用明显较小。此外，还公开了具有这些选择性活性的金属蛋白酶抑制剂化合物，制造这种化合物的过程以及使用抑制剂的制药组合物。
• AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
  申请人：——

  公开号：US20010014688A1

  公开（公告）日：2001-08-16

  A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

  本发明涉及一种治疗过程，包括向患有与病理基质金属蛋白酶活性相关的状况的宿主施用有效量的芳香磺酮羟肟酸，该芳香磺酮羟肟酸表现出优异的抑制活性，可抑制一种或多种基质金属蛋白酶(MMP)酶，如MMP-2、MMP-9和MMP-13，同时对MMP-1的抑制显著较少。还揭示了具有这些选择性活性的金属蛋白酶抑制剂化合物、制造这种化合物的工艺以及使用抑制剂的制药组合物。
• Aromatic sulfone hydroxamic acid metalloprotease inhibitor
  申请人：——

  公开号：US20020177588A1

  公开（公告）日：2002-11-28

  A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

  本发明揭示了一种治疗过程，包括向患有与病理性基质金属蛋白酶活性相关的病症的宿主施用一种有效量的芳香族磺酰羟肟酸，该芳香族磺酰羟肟酸在MMP-2、MMP-9和MMP-13等一种或多种基质金属蛋白酶（MMP）酶活性上表现出优异的抑制活性，同时在至少MMP-1的抑制上表现出明显较少的抑制。还揭示了具有这些选择性活性的金属蛋白酶抑制剂化合物、制造这种化合物的过程以及使用抑制剂的制药组合物。